Brief: Alpha Tau Announces FDA Approval Of Ide To Initiate Multi-Center Pivotal Study Of Alpha Dart
08/06/2022 14:12
June 8 (Reuters) - Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES FDA APPROVAL OF IDE TO INITIATE
MULTI-CENTER
PIVOTAL STUDY OF ALPHA DART™ IN RECURRENT CUTANEOUS SCC
Source text for Eikon: ID:nPnbB2SmKa
Further company coverage: DRTS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer